{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:24:21Z","timestamp":1780604661230,"version":"3.54.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Centre of Postgraduate Medical Education","award":["501-1-10-14-20\/21"],"award-info":[{"award-number":["501-1-10-14-20\/21"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Radial access is preferred in patients with chronic coronary syndromes (CCSs) treated with ad hoc percutaneous coronary intervention (PCI). Antithrombotic and antiplatelet treatment before PCI may affect outcomes at vascular access sites. QuikClot Radial is a kaolin-based band that may shorten hemostasis time. Using point-of-care testing, we investigated the effect of antithrombotic and antiplatelet treatment on access-site complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective observational study included consecutive patients with CCS on chronic aspirin therapy referred for ad hoc PCI. The activated clotting time (ACT), global thrombosis test and VerifyNow P2Y<jats:sub>12<\/jats:sub> test were done sequentially after unfractionated heparin (UFH) and clopidogrel administration. Patients were monitored for radial artery patency, bleeding and local hematoma until discharge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We enrolled 40 patients [mean age, 68.8\u2005\u00b1\u20058.8 years; men, 30 (75%)] who received UFH (median dose, 8000\u2005IU; interquartile range, 7000\u20139000\u2005IU) and clopidogrel (600\u2005mg). All radial arteries remained patent during follow-up. Local bleeding and hematomas were noted in 11 patients (27.5%) each. Patients with bleeding had lower mean platelet activity at 2\u2005h [122.5\u2005\u00b1\u200551 platelet reactivity units (PRU) vs. 158.7\u2005\u00b1\u200543 PRU, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.04] and higher ACT (216.9\u2005\u00b1\u200540\u2009s vs. 184.6\u2005\u00b1\u200528\u2009s, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006) than patients without bleeding. An ACT &gt;196\u2005s at 2\u2005h predicted bleeding or hematoma (AUC, 0.72; 95% CI, 0.56\u20130.85, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Lower platelet activity and higher ACT after PCI were associated with higher bleeding risk at a vascular access site. Point-of-care testing of ACT after the procedure may help identify patients with CCS undergoing PCI who are at higher risk of access-site bleeding.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001336","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:00:49Z","timestamp":1705665649000},"page":"292-298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Platelet reactivity and activated clotting time predict hemorrhagic site complications in patients with chronic coronary syndromes undergoing percutaneous coronary interventions"],"prefix":"10.1097","volume":"35","author":[{"given":"Bogumi\u0142","family":"Ramotowski","sequence":"first","affiliation":[{"name":"Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"S\u0142omski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"R1-20250729","first-page":"472","article-title":"Outcomes of same-day discharge following percutaneous coronary intervention in a rural population.","volume":"102","author":"Ginete","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"e00268","DOI":"10.1161\/JAHA.115.002686","article-title":"Radial artery occlusion after transradial interventions: a systematic review and meta-analysis.","volume":"5","author":"Rashid","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jama.1966.03100180108036","article-title":"Activated coagulation time of whole blood.","volume":"196","author":"Hattersley","year":"1966","journal-title":"JAMA"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/CIRCULATIONAHA.104.478222","article-title":"Coagulation assays.","volume":"112","author":"Bates","year":"2005","journal-title":"Circulation"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"728S","DOI":"10.1378\/chest.114.5_Supplement.728S","article-title":"Antithrombotic therapy in patients undergoing coronary angioplasty.","volume":"114","author":"Popma","year":"1998","journal-title":"Chest"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/01.CIR.93.4.667","article-title":"Relation between activated clotting time during angioplasty and abrupt closure.","volume":"93","author":"Narins","year":"1996","journal-title":"Circulation"},{"key":"R9-20250729","first-page":"2","article-title":"The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty Heparin Registry Investigators.","volume":"7","author":"Ferguson","year":"1995","journal-title":"J Invasive Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0002-8703(92)90793-U","article-title":"The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty.","volume":"123","author":"McGarry","year":"1992","journal-title":"Am Heart J"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(02)02767-5","article-title":"Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.","volume":"41","author":"Tolleson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/hrt.2010.195438","article-title":"Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.","volume":"97","author":"Siller-Matula","year":"2011","journal-title":"Heart"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jcin.2012.01.009","article-title":"A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.","volume":"5","author":"Mangiacapra","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1055\/s-0038-1649484","article-title":"Peri-procedural platelet reactivity in percutaneous coronary intervention.","volume":"118","author":"Alexopoulos","year":"2018","journal-title":"Thromb Haemost"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2012.03.022","article-title":"Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.","volume":"164","author":"Jeong","year":"2012","journal-title":"Am Heart J"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk.","volume":"65","author":"Okafor","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"e13471","DOI":"10.1111\/eci.13471","article-title":"Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment.","volume":"51","author":"Kanji","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.thromres.2014.02.018","article-title":"Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.","volume":"133","author":"Yamamoto","year":"2014","journal-title":"Thromb Res"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001721-200301000-00007","article-title":"G\u00f6r\u00f6g Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.","volume":"14","author":"Yamamoto","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/europace\/euz176","article-title":"Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.","volume":"21","author":"Spinthakis","year":"2019","journal-title":"Europace"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.","volume":"55","author":"Saraf","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehs300","article-title":"Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease.","volume":"34","author":"Sharma","year":"2013","journal-title":"Eur Heart J"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.jacc.2023.03.388","article-title":"Biomarkers of thrombotic status predict spontaneous reperfusion in patients with ST-segment elevation myocardial infarction.","volume":"81","author":"Kanji","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00380-019-01520-z","article-title":"Efficacy and safety of kaolin-based hemostatic pad vs standard mechanical compression following transradial and transulnar access for elective coronary angiography and PCI: RAUL trial substudy.","volume":"35","author":"Lewandowski","year":"2020","journal-title":"Heart Vessels"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/02184923211027790","article-title":"Role of trans-radial band protocols in radial artery occlusion: randomized trial.","volume":"30","author":"Rahman","year":"2021","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"2345584","DOI":"10.1155\/2022\/2345584","article-title":"Study on the safety of the new radial artery hemostasis device.","volume":"2022","author":"Wu","year":"2022","journal-title":"J Interv Cardiol"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty.","volume":"23","author":"Ferguson","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0735-1097(01)01344-4","article-title":"ACC\/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty).","volume":"37","author":"Smith","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"e006084","DOI":"10.1161\/CIRCINTERVENTIONS.118.006084","article-title":"Activated clotting time to guide heparin dosing in non-ST-segment-elevation acute coronary syndrome patients undergoing percutaneous coronary intervention and treated with IIb\/IIIa Inhibitors: impact on ischemic and bleeding outcomes: insights from the TAO trial.","volume":"11","author":"Dillinger","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1540-8183.2010.00584.x","article-title":"Randomized clinical trial on short-time compression with Kaolin-filled pad: a new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention.","volume":"24","author":"Politi","year":"2011","journal-title":"J Interv Cardiol"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/jcm9113607","article-title":"Impact of the use of a larger forearm artery on the efficacy and safety of transradial and translunar access: a randomized trial with preprocedural ultrasonography.","volume":"9","author":"Lewandowski","year":"2020","journal-title":"J Clin Med"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/jcm10051099","article-title":"The impact of using a larger forearm artery for percutaneous coronary interventions on hand strength: a randomized controlled trial.","volume":"10","author":"Lewandowski","year":"2021","journal-title":"J Clin Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:02:06Z","timestamp":1753812126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001336","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}